Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.

BACKGROUND:Two large-scale efficacy studies with the recombinant yellow fever-17D-dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant protection against dengue disease during two years...

Full description

Bibliographic Details
Published in:PLOS Neglected Tropical Diseases
Main Authors: Anke Harenberg, Aymeric de Montfort, Frédérique Jantet-Blaudez, Matthew Bonaparte, Florence Boudet, Melanie Saville, Nicholas Jackson, Bruno Guy
Format: Article in Journal/Newspaper
Language:English
Published: Public Library of Science (PLoS) 2016
Subjects:
Online Access:https://doi.org/10.1371/journal.pntd.0004830
https://doaj.org/article/ca06e209e1fd4560b77f9a3fb56471c0
id ftdoajarticles:oai:doaj.org/article:ca06e209e1fd4560b77f9a3fb56471c0
record_format openpolar
spelling ftdoajarticles:oai:doaj.org/article:ca06e209e1fd4560b77f9a3fb56471c0 2023-05-15T15:07:20+02:00 Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials. Anke Harenberg Aymeric de Montfort Frédérique Jantet-Blaudez Matthew Bonaparte Florence Boudet Melanie Saville Nicholas Jackson Bruno Guy 2016-07-01T00:00:00Z https://doi.org/10.1371/journal.pntd.0004830 https://doaj.org/article/ca06e209e1fd4560b77f9a3fb56471c0 EN eng Public Library of Science (PLoS) http://europepmc.org/articles/PMC4961416?pdf=render https://doaj.org/toc/1935-2727 https://doaj.org/toc/1935-2735 1935-2727 1935-2735 doi:10.1371/journal.pntd.0004830 https://doaj.org/article/ca06e209e1fd4560b77f9a3fb56471c0 PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004830 (2016) Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2016 ftdoajarticles https://doi.org/10.1371/journal.pntd.0004830 2022-12-31T05:29:48Z BACKGROUND:Two large-scale efficacy studies with the recombinant yellow fever-17D-dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant protection against dengue disease during two years' active surveillance (active phase). Long-term follow up of participants for breakthrough disease leading to hospitalization is currently ongoing (hospital phase). METHODOLOGY/PRINCIPAL FINDINGS:We assessed the cytokine profile in acute sera from selected participants hospitalized (including during the active phase) up to the beginning of the second year of long-term follow up for both studies. The serum concentrations of 38 cytokines were measured in duplicate using the Milliplex Human Cytokine MAGNETIC BEAD Premixed 38 Plex commercial kit (Millipore, Billerica, MA, USA). Partial least squares discriminant analyses did not reveal any difference in the overall cytokine profile of CYD-TDV and placebo recipients hospitalized for breakthrough dengue regardless of stratification used. In addition, there was no difference in the cytokine profile for breakthrough dengue among those aged <9 years versus those aged ≥ 9 years. CONCLUSIONS/SIGNIFICANCE:These exploratory findings show that CYD-TDV does not induce a particular immune profile versus placebo, corroborating the clinical profile observed. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic PLOS Neglected Tropical Diseases 10 7 e0004830
institution Open Polar
collection Directory of Open Access Journals: DOAJ Articles
op_collection_id ftdoajarticles
language English
topic Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
spellingShingle Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
Anke Harenberg
Aymeric de Montfort
Frédérique Jantet-Blaudez
Matthew Bonaparte
Florence Boudet
Melanie Saville
Nicholas Jackson
Bruno Guy
Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
topic_facet Arctic medicine. Tropical medicine
RC955-962
Public aspects of medicine
RA1-1270
description BACKGROUND:Two large-scale efficacy studies with the recombinant yellow fever-17D-dengue virus, live-attenuated, tetravalent dengue vaccine (CYD-TDV) candidate undertaken in Asia (NCT01373281) and Latin America (NCT01374516) demonstrated significant protection against dengue disease during two years' active surveillance (active phase). Long-term follow up of participants for breakthrough disease leading to hospitalization is currently ongoing (hospital phase). METHODOLOGY/PRINCIPAL FINDINGS:We assessed the cytokine profile in acute sera from selected participants hospitalized (including during the active phase) up to the beginning of the second year of long-term follow up for both studies. The serum concentrations of 38 cytokines were measured in duplicate using the Milliplex Human Cytokine MAGNETIC BEAD Premixed 38 Plex commercial kit (Millipore, Billerica, MA, USA). Partial least squares discriminant analyses did not reveal any difference in the overall cytokine profile of CYD-TDV and placebo recipients hospitalized for breakthrough dengue regardless of stratification used. In addition, there was no difference in the cytokine profile for breakthrough dengue among those aged <9 years versus those aged ≥ 9 years. CONCLUSIONS/SIGNIFICANCE:These exploratory findings show that CYD-TDV does not induce a particular immune profile versus placebo, corroborating the clinical profile observed.
format Article in Journal/Newspaper
author Anke Harenberg
Aymeric de Montfort
Frédérique Jantet-Blaudez
Matthew Bonaparte
Florence Boudet
Melanie Saville
Nicholas Jackson
Bruno Guy
author_facet Anke Harenberg
Aymeric de Montfort
Frédérique Jantet-Blaudez
Matthew Bonaparte
Florence Boudet
Melanie Saville
Nicholas Jackson
Bruno Guy
author_sort Anke Harenberg
title Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
title_short Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
title_full Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
title_fullStr Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
title_full_unstemmed Cytokine Profile of Children Hospitalized with Virologically-Confirmed Dengue during Two Phase III Vaccine Efficacy Trials.
title_sort cytokine profile of children hospitalized with virologically-confirmed dengue during two phase iii vaccine efficacy trials.
publisher Public Library of Science (PLoS)
publishDate 2016
url https://doi.org/10.1371/journal.pntd.0004830
https://doaj.org/article/ca06e209e1fd4560b77f9a3fb56471c0
geographic Arctic
geographic_facet Arctic
genre Arctic
genre_facet Arctic
op_source PLoS Neglected Tropical Diseases, Vol 10, Iss 7, p e0004830 (2016)
op_relation http://europepmc.org/articles/PMC4961416?pdf=render
https://doaj.org/toc/1935-2727
https://doaj.org/toc/1935-2735
1935-2727
1935-2735
doi:10.1371/journal.pntd.0004830
https://doaj.org/article/ca06e209e1fd4560b77f9a3fb56471c0
op_doi https://doi.org/10.1371/journal.pntd.0004830
container_title PLOS Neglected Tropical Diseases
container_volume 10
container_issue 7
container_start_page e0004830
_version_ 1766338866548047872